Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer

Although nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is approved to be given every 3 weeks, weekly use of this drug is becoming a new standard of care in patients with metastatic breast cancer (MBC). This prospective Phase II study was conducted to improve the efficacy of weekly nab-pacli...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Si, Tang, Lichen, Zhang, Jian, Lv, Fangfang, Wang, Zhonghua, Wang, Leiping, Zhang, Qunling, Zheng, Chunlei, Qiu, Lixin, Jia, Zhen, Lu, Yunhua, Liu, Guangyu, Shao, Zhimin, Wang, Biyun, Hu, Xichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964033/
https://www.ncbi.nlm.nih.gov/pubmed/24672237
http://dx.doi.org/10.2147/IJN.S58275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964033/
https://www.ncbi.nlm.nih.gov/pubmed/24672237
http://dx.doi.org/10.2147/IJN.S58275

Ejemplares similares